A koleszterinszint célértékre csökkenté sének lehetoségei statinokkal

Translated title of the contribution: Lowering the cholesterol level to the target value by statins

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The clinical application of statins has opened new perspectives in the therapy of atherosclerosis. Clinical studies have provided firm evidence that the achievement of the recommended lipid values in cardiovascular patients stops, or even reverses, the progression of atherosclerosis. Beside the cholesterol lowering effect this result is due to a complex vasoprotective, so-called pleiotropic mechanism. In the past two years a number of interventional trials confirmed that the lower the low density lipoprotein cholesterol level is reduced to, the lower the patient's cardiovascular risk. Based on international epidemiological trials the target value of the low density lipoprotein cholesterol of the most seriously ill, very high risk patients was defined as 1.8 mmol/l. The available statin preparations have only been able to achieve this low level of low density lipoprotein cholesterol in a portion of patients. Rosuvastatin, a recently developed statin derivative, however, can be successfully used even in monotherapy to achieve the target low density lipoprotein cholesterol value in the majority of patients with high cardiovascular risk. As part of the Galaxy program, a large study on the antiinflammatory and antiatherosclerotic properties of rosuvastatin will be conducted in the near future.

Original languageHungarian
Pages (from-to)114-120
Number of pages7
JournalLege Artis Medicinae
Volume16
Issue number2
Publication statusPublished - Feb 2006

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Cholesterol
Atherosclerosis
Galaxies
Anti-Inflammatory Agents
Lipids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A koleszterinszint célértékre csökkenté sének lehetoségei statinokkal. / Karádi, I.

In: Lege Artis Medicinae, Vol. 16, No. 2, 02.2006, p. 114-120.

Research output: Contribution to journalArticle

@article{4eedbe3eba3a485cb616fa1d55fd9359,
title = "A koleszterinszint c{\'e}l{\'e}rt{\'e}kre cs{\"o}kkent{\'e} s{\'e}nek lehetos{\'e}gei statinokkal",
abstract = "The clinical application of statins has opened new perspectives in the therapy of atherosclerosis. Clinical studies have provided firm evidence that the achievement of the recommended lipid values in cardiovascular patients stops, or even reverses, the progression of atherosclerosis. Beside the cholesterol lowering effect this result is due to a complex vasoprotective, so-called pleiotropic mechanism. In the past two years a number of interventional trials confirmed that the lower the low density lipoprotein cholesterol level is reduced to, the lower the patient's cardiovascular risk. Based on international epidemiological trials the target value of the low density lipoprotein cholesterol of the most seriously ill, very high risk patients was defined as 1.8 mmol/l. The available statin preparations have only been able to achieve this low level of low density lipoprotein cholesterol in a portion of patients. Rosuvastatin, a recently developed statin derivative, however, can be successfully used even in monotherapy to achieve the target low density lipoprotein cholesterol value in the majority of patients with high cardiovascular risk. As part of the Galaxy program, a large study on the antiinflammatory and antiatherosclerotic properties of rosuvastatin will be conducted in the near future.",
keywords = "Cardiovascular risk, Low density lipoprotein cholesterol, Target value",
author = "I. Kar{\'a}di",
year = "2006",
month = "2",
language = "Hungarian",
volume = "16",
pages = "114--120",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "2",

}

TY - JOUR

T1 - A koleszterinszint célértékre csökkenté sének lehetoségei statinokkal

AU - Karádi, I.

PY - 2006/2

Y1 - 2006/2

N2 - The clinical application of statins has opened new perspectives in the therapy of atherosclerosis. Clinical studies have provided firm evidence that the achievement of the recommended lipid values in cardiovascular patients stops, or even reverses, the progression of atherosclerosis. Beside the cholesterol lowering effect this result is due to a complex vasoprotective, so-called pleiotropic mechanism. In the past two years a number of interventional trials confirmed that the lower the low density lipoprotein cholesterol level is reduced to, the lower the patient's cardiovascular risk. Based on international epidemiological trials the target value of the low density lipoprotein cholesterol of the most seriously ill, very high risk patients was defined as 1.8 mmol/l. The available statin preparations have only been able to achieve this low level of low density lipoprotein cholesterol in a portion of patients. Rosuvastatin, a recently developed statin derivative, however, can be successfully used even in monotherapy to achieve the target low density lipoprotein cholesterol value in the majority of patients with high cardiovascular risk. As part of the Galaxy program, a large study on the antiinflammatory and antiatherosclerotic properties of rosuvastatin will be conducted in the near future.

AB - The clinical application of statins has opened new perspectives in the therapy of atherosclerosis. Clinical studies have provided firm evidence that the achievement of the recommended lipid values in cardiovascular patients stops, or even reverses, the progression of atherosclerosis. Beside the cholesterol lowering effect this result is due to a complex vasoprotective, so-called pleiotropic mechanism. In the past two years a number of interventional trials confirmed that the lower the low density lipoprotein cholesterol level is reduced to, the lower the patient's cardiovascular risk. Based on international epidemiological trials the target value of the low density lipoprotein cholesterol of the most seriously ill, very high risk patients was defined as 1.8 mmol/l. The available statin preparations have only been able to achieve this low level of low density lipoprotein cholesterol in a portion of patients. Rosuvastatin, a recently developed statin derivative, however, can be successfully used even in monotherapy to achieve the target low density lipoprotein cholesterol value in the majority of patients with high cardiovascular risk. As part of the Galaxy program, a large study on the antiinflammatory and antiatherosclerotic properties of rosuvastatin will be conducted in the near future.

KW - Cardiovascular risk

KW - Low density lipoprotein cholesterol

KW - Target value

UR - http://www.scopus.com/inward/record.url?scp=33644604259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644604259&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33644604259

VL - 16

SP - 114

EP - 120

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 2

ER -